AUS
NZ
UK
CA
USA
IND
Healthcare
Spire Healthcare Completes Execution of Share Buyback Program
November 18, 2024 09:56 AM GMT| By Team Kalkine MediaHighlights:,Spire Healthcare Group PLC has initiated a share buyback program, repurchasing 50,000 shares.,The share buyback reduces the total number of shares in circulation to 403,594,688.,Spire Healthcare remains a significant entity in the UK heal...
Halma plc (HLMA: LSE) Expands Healthcare Sector with Acquisition of Lamidey Noury Medical
November 18, 2024 07:25 AM GMT| By Team Kalkine MediaHighlights:,Halma acquires Lamidey Noury Medical for €50m (£42m) to enhance its portfolio of advanced medical technologies.,Lamidey Noury, based in France, manufactures electrosurgical devices for minimally invasive surgery, with products sold in ove...
Pharma Stocks Sink After Trump's Controversial Health Secretary Appointment
November 15, 2024 03:35 PM GMT| By Team Kalkine MediaHighlights:,Pharma Market Shock:,Appointment of vaccine critic Robert F Kennedy Jr as US health secretary spooked global pharmaceutical and biotech stocks, triggering a sharp sell-off.,Vaccine Makers Hit Hard:,Shares in Moderna, BioNTech, Pfizer, and...
ANGLE PLC’s Liquid Biopsy Technology Paves the Way for Breakthroughs in Cancer Diagnostics
November 15, 2024 09:35 AM GMT| By Team Kalkine MediaHighlights:,Innovative Liquid Biopsy Advances:,ANGLE PLC presented new data on Parsortix-based assays for lung and breast cancer diagnostics, highlighting its potential to revolutionise personalised treatment.,Improved Detection of PD-L1 and HER2 Mar...
Pharma Stocks Sink as Trump's Health Secretary Appointment Sparks Market Fears
November 15, 2024 08:30 AM GMT| By Team Kalkine MediaHighlights:,Market Reaction,:,GSK and AstraZeneca lost,nearly £7 billion,in combined market value following the appointment of Robert F Kennedy Jr., a known vaccine skeptic, as the new US Health Secretary.,Sector Uncertainty,:,The pharmaceutical indu...
PDS Biotech Streamlines Clinical Trials Amid Positive Pipeline Developments
November 14, 2024 08:36 AM GMT| By Team Kalkine MediaHighlights:,Optimized Phase 3 Trial Design,: PDS Biotech revises VERSATILE-003 trial for cost and timeline efficiency, seeking FDA clearance.,Promising Clinical Data,: Versamune® HPV shows strong safety and efficacy in ongoing studies, including cerv...
AstraZeneca Raises Full-Year Forecast as Oncology Portfolio Drives Strong Growth
November 13, 2024 12:00 AM GMT| By Team Kalkine MediaHighlights:,Upgraded Sales and Earnings Forecast:,AstraZeneca raised its 2024 guidance for both sales and earnings for the second time in four months, now expecting high-teens growth in revenue and earnings per share.,Robust Oncology Performance:,The...
AstraZeneca Faces Uncertainty Amid Chinese Criminal Probe as Business Grows
November 13, 2024 12:00 AM GMT| By Team Kalkine MediaHighlights:,AstraZeneca under Investigation:,Chinese authorities have detained AstraZeneca's top executives, including its China president, over allegations of illegal importation of oncology medicines.,CEO’s Commitment to Cooperation:,Pascal Soriot...
AstraZeneca Boosts 2024 Sales Forecast, Unveils $3.5 Billion U.S. Expansion Amid Rising Drug Demand
November 12, 2024 04:56 PM GMT| By Team Kalkine MediaHighlights,AstraZeneca raises full-year sales outlook, forecasting high-teens percentage growth.,Plans $3.5 billion U.S. investment by 2026, creating over 1,000 skilled jobs.,Reports strong Q3 results, beating revenue and earnings projections.,Britis...
ConvaTec Raises Full-Year Outlook as Strong Revenue Growth Boosts Confidence
November 12, 2024 04:52 PM GMT| By Team Kalkine MediaHighlights:,●,Upgraded Guidance:,ConvaTec raises its full-year organic revenue growth forecast to 7.25-8.0% from 5-7%.,●,Improved Profit Margin:,Adjusted operating profit margin outlook increased to at least 21.5%.,●,Positive Market Reaction:,Shares...
23andMe Cuts 40% of Staff, Exits Therapeutics Amid Financial Strain
November 12, 2024 04:25 PM GMT| By Team Kalkine MediaHighlights:,Workforce and Strategy Overhaul,: 23andMe cuts 40% of staff and halts therapeutics programs to focus on core genetics business, targeting $35 million in savings.,Data Breach and Legal Settlement,: A major breach affected 6.9 million users...
Could Polarean Imaging’s New VP Truly Drive Growth in Lung Imaging?
November 12, 2024 11:11 AM GMT| By Team Kalkine MediaHighlights,Polarean Imaging focuses on advancements in functional lung imaging technology.,The company has set a higher revenue target, emphasizing growth in the medical imaging sector.,A new VP has introduced a strategic approach to boost Polarean's...
AstraZeneca Unveils Ambitious $3.5 Billion Expansion Plan in the U.S.
November 12, 2024 08:37 AM GMT| By Team Kalkine MediaHighlights:,Major U.S. Investment:,AstraZeneca to invest $3.5 billion in expanding its R&D and manufacturing capabilities across the U.S. by 2026.,Job Creation:,The plan includes $2 billion earmarked to generate over 1,000 high-skilled jobs in the ph...
GSK Downgraded as Analysts Cite Limited Near-Term Growth Prospects
November 12, 2024 08:37 AM GMT| By Team Kalkine MediaHighlights:,Jefferies Downgrades GSK:,US bank Jefferies has reduced GSK's rating to 'hold,' citing a lack of upcoming catalysts for growth.,Concerns Over Vaccine Performance:,Analysts pointed to uncertainties surrounding GSK’s Shingrix (Shingles) and...
AstraZeneca and Amgen Announce Positive Phase III Results for Tezspire in Treating Nasal Polyps
November 08, 2024 09:10 AM GMT| By Team Kalkine MediaHighlights:,Significant Symptom Relief,:,Tezspire,(,tezepelumab,) reduced nasal polyp size and congestion in patients with chronic rhinosinusitis.,New Treatment Potential,:,The study suggests a promising alternative for patients with limited options,...
Indivior Engages with Activist Investor Oaktree Amid Calls for Board Overhaul
November 08, 2024 08:50 AM GMT| By Team Kalkine MediaHighlights:,Oaktree Challenges Indivior Board,:,Activist investor Oaktree Capital seeks a major shake-up of Indivior’s board, citing concerns over strategy and spending.,Indivior Remains Open to Dialogue,:,The specialty pharma firm has been in active...
AstraZeneca Grapples with Market Uncertainty Following Value Decline
November 08, 2024 08:37 AM GMT| By Team Kalkine MediaHighlights:,Significant Market Decline:,AstraZeneca has seen its market value drop by £50 billion since September, driven by concerns over its drug pipeline and China operations.,Pipeline Worries:,Disappointing trial results for the dato-DXd cancer d...
Positive Tezspire Trial Results Generate Enthusiasm at AstraZeneca
November 08, 2024 08:16 AM GMT| By Team Kalkine MediaHighlights:,AstraZeneca announces positive results from the Phase III WAYPOINT trial for Tezspire (tezepelumab), a treatment for nasal polyps.,The trial demonstrated a statistically significant reduction in nasal polyp size and improved nasal congest...
Spire Healthcare Finalizes Strategic Share Buyback
November 08, 2024 08:01 AM GMT| By Team Kalkine MediaHighlights:,Spire Healthcare Group PLC has completed the repurchase of 50,000 of its shares on the London Stock Exchange.,The shares were repurchased at prices ranging from 216 to 218 pence each, as part of the company’s ongoing buyback program.,The...
Roquefort Therapeutics Advances Growth Plans with Loan Note Conversion
November 07, 2024 07:25 AM GMT| By Team Kalkine MediaHighlights:,Roquefort Therapeutics PLC converts convertible loan notes into new shares.,The move is part of the company’s strategy to expand in immunology and oncology.,New shares will be admitted to trading on the London Stock Exchange.,Roquefort Th...
